Parkinson’s disease - Articles and news items

Amarantus forms Elto Pharma for CNS Disorders and MANF Therapeutics for Ophthalmology

Industry news / 18 April 2017 / Niamh Marriott, Junior Editor

Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus’ mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer’s Aggression and Parkinson’s disease Levodopa-induced Dyskinesia (PD-LID). Concurrently, Amarantus has formed the […]

Success for Renown’s Phase I study to treat “OFF” episodes in Parkinson’s patients

Industry news / 22 March 2017 / Niamh Marriott, Junior Editor

The study intended to compare the plasma concentrations of sub-lingual apomorphine spray against the currently approved formulation…

Prothena’s Phase 1b Parkinson’s disease study showed robust antibody CNS penetration

Industry news / 11 November 2016 / Niamh Louise Marriott, Digital Content Producer

Prothena’s Phase 1b multiple ascending dose study of PRX002 trial found an acceptable safety and tolerability profile in patients with Parkinson’s disease…

Prexton successfully completes phase 1 Parkinson’s disease trial

Industry news / 20 September 2016 / Niamh Louise Marriott, Digital Content Producer

This study was the first in man Phase 1 clinical trial for an mGluR4 positive allosteric modulator. The randomised, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of PXT002331 dosed orally…

Biomarker breakthrough could improve Parkinson’s treatment

Industry news / 16 August 2016 / University of Florida

Scientists have found that using magnetic resonance imaging reveals areas where Parkinson’s disease causes progressive decline in brain activity, a biomarker discovery which will help to evaluate new experimental treatments to slow or stop the disease’s progression…

Collaboration to explore nilotinib as a potential treatment for Parkinson’s

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Preclinical studies have shown that cancer drug nilotinib may protect neuronal cells from Parkinson’s pathology by inhibiting the activity of c-Abl…

Parkinson’s disease therapy safinamide launches in the UK

Industry news / 23 May 2016 / Victoria White, Digital Content Producer

Commenting on the launch, Maurizio Castorina, CEO of Zambon, said safinamide offers PD patients “a novel therapeutic option”…

FDA approves Nuplazid to treat hallucinations in Parkinson’s disease

Industry news / 3 May 2016 / Victoria White, Digital Content Producer

The FDA has approved Acadia’s Nuplazid, the first drug approved to treat hallucinations and delusions experienced by some people with Parkinson’s disease…

Parkinson’s disease market to hit $3.2 billion by 2021

Industry news / 25 February 2016 / Victoria White

GBI Research states that Parkinson’s disease market growth will occur despite the patent expiries of several key products during the forecast period…

Acorda to acquire Biotie; gains rights to tozadenant

Industry news / 19 January 2016 / Victoria White

In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease…

Parkinson’s disease treatment pipeline holds significant potential, says GBI Research

Industry news / 12 January 2016 / Victoria White

An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets…

Nilotinib improved cognition and motor skills in Parkinson’s trial

Industry news / 19 October 2015 / Victoria White

Nilotinib, a treatment for leukaemia, improved cognition, motor skills and non-motor function in patients with Parkinson’s disease in a Phase I clinical trial…

  • Page 1 of 2
  • 1
  • 2
  • >

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+